Fig. 1From: QSAR, molecular docking studies, ligand-based design and pharmacokinetic analysis on Maternal Embryonic Leucine Zipper Kinase (MELK) inhibitors as potential anti-triple-negative breast cancer (MDA-MB-231 cell line) drug compoundsa Parthenolide template molecule for Table 1. b Parthenolide template molecule 2 for Table 2. c Parthenolide template molecule 3 for Table 3. d Parthenolide template molecule 4 for Table 4Back to article page